<DOC>
	<DOCNO>NCT01569750</DOCNO>
	<brief_summary>The purpose study identify , dose , ibrutinib may administer R-CHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ) document response combination patient newly diagnose diffuse large B-cell lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>A Study Combining Ibrutinib With Rituximab , Cyclophosphamide , Doxorubicin , Vincristine , Prednisone Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma</brief_title>
	<detailed_description>This open-label ( individual know identity study treatment ) , dose escalation study establish recommend dose ibrutinib combine standard R-CHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ) approximately 33 adult CD20-positive B-cell non-Hodgkin lymphoma ( NHL ) R-CHOP appropriate therapy . There 3 period study : pretreatment ( screen ) period 28 day enrollment ; open-label treatment period ( 6 cycle ibrutinib R-CHOP ; end end-of-treatment visit ) ; posttreatment follow-up period end study ( maximum 1 year last patient complete end-of-treatment visit ) . There 2 part study ( dose escalation [ Part 1 ] expansion [ Part 2 ] ) . During dose escalation period , `` 3+3 '' design apply approximately 18 patient CD20 positive B cell NHL ( diffuse large B-cell lymphoma [ DLBCL ] , mantle cell lymphoma [ MCL ] , follicular lymphoma [ FL ] ) may enrol . Patients assign cohort increase oral daily dos ibrutinib ( 280 , 420 , 560 mg ) administer combination R-CHOP . The maximum tolerated dose ( MTD ) , assess Cycle 1 ( dose-limiting toxicity [ DLT ] period ) , define high dose combination regimen &lt; =33 % patient experience DLT . Baseline follow-up electrocardiogram perform throughout study . A Study Evaluation Team review available data upon completion first cycle patient dose cohort determine DLTs , dose escalation acceptable , subsequently determine recommended Phase 2 dose . Once recommended Phase 2 dose determine , approximately 15 patient newly diagnose DLBCL enter expansion cohort dose level select assess safety , pharmacokinetics , pharmacodynamics , pharmacogenomics , activity combination . Patients whose disease progress end Cycle 1 continue receive ibrutinib R CHOP maximum 6 cycle . During posttreatment follow-up period , long term safety , survival status , disease progression , subsequent antilymphoma therapy collect . The study end 1 year last patient complete end treatment visit .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histopathologicallyconfirmed CD20positive Bcell non Hodgkin lymphoma disease RCHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ) appropriate therapy ( diffuse large Bcell lymphoma , mantle cell lymphoma , follicular lymphoma ) ; expansion cohort , least 1 cohort include patient newly diagnose diffuse large Bcell lymphoma Stage I AX ( bulk define single lymph node mass &gt; =10 cm diameter ) Stage IV disease At least 1 measurable site disease base Revised Response Criteria Malignant Lymphoma Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 Adequate bone marrow , liver , renal function History protocoldefined disallowed therapy Prior multidrug chemotherapy treatment lymphoma History stroke intracranial hemorrhage within 6 month prior first dose study drug Major surgery within 3 week enrollment Known bleeding diatheses , platelet dysfunction disorder , require therapeutic anticoagulation Known lymphoma central nervous system Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , New York Heart Association Class III IV heart failure , uncontrolled angina , pericardial disease , cardiac amyloidosis , clinically significant cardiac arrhythmia , leave ventricular ejection fraction outside institutional limit Active systemic infection require treatment include hepatitis B hepatitis C infection Documented suspect human immunodeficiency virus infection Diagnosed treated malignancy nonHodgkin lymphoma except ; adequately treat nonmelanoma skin cancer , curatively treated situ cancer cervix , ductal carcinoma situ breast , solid tumor curatively treat evidence disease &gt; 5 year Has condition , opinion investigator , would make study participation best interest ( eg , compromise wellbeing ) patient could prevent , limit , confound protocolspecified assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>CD20-positive B-cell non-Hodgkin lymphoma</keyword>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Follicular lymphoma</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>R-CHOP</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisone</keyword>
</DOC>